GlassScriptPhysician profile
Isabella G Chen
NPI 1053621730
$1,074.78
in general payments reported to CMS, 2019-2025
19 companies · $70.85 in 2025
The $70.85 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.83 · 2020: $41.79 · 2021: $308 · 2022: $320 · 2023: $265 · 2025: $70.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $306 · Education: $30.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $305.69 |
| Education | $30.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $181.09 | 2021-2025 | Jaypirca, Verzenio |
| Astrazeneca Pharmaceuticals LP | $165.06 | 2021-2023 | Calquence |
| E.R. Squibb & Sons, L.L.C. | $91.52 | 2019-2022 | |
| Seagen INC. | $82.01 | 2020-2022 | |
| Pfizer INC. | $81.89 | 2019-2025 | |
| Gilead Sciences, INC. | $80.67 | 2021-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $66.81 | 2019-2023 | Imbruvica, Epkinly |
| Genentech USA, INC. | $50.01 | 2021-2022 | |
| Servier Pharmaceuticals LLC | $38.36 | 2023 | |
| Abbvie INC. | $37.31 | 2023-2025 | Venclexta |
| Aveo Pharmaceuticals, INC. | $36.47 | 2022-2023 | Fotivda |
| Immunogen, INC. | $27.01 | 2023 | Elahere |
| Array Biopharma INC | $26.03 | 2021 | |
| Karyopharm Therapeutics INC. | $21.61 | 2021 | |
| Glaxosmithkline, LLC. | $21.35 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| G1 Therapeutics, INC. | $19.59 | 2023 | Cosela |
| Sobi, INC | $18.12 | 2022 | |
| Emd Serono, INC. | $17.45 | 2023 | Tepmetko |
| Janssen Pharmaceuticals, INC | $12.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isabella Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.